Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment save search
Veru Announces Presentation of Phase 3 Study of Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Published: 2022-08-09 (Crawled : 15:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.86%
H: 0.53%
C: -0.68%
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: -0.5%
H: 2.25%
C: -4.17%
covid-19 treatment risk sabizabulin respiratory presentation study
Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder
Published: 2022-08-09 (Crawled : 13:20) - biospace.com/
RLMD | $3.85 -1.54% -1.56% 110K
|
Health Technology
|
| O: 1.56%
H: 0.11%
C: -2.43%
rel-1017 treatment fda designation therapeutics fast track designation major depressive disorder
Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich’s Ataxia
Published: 2022-08-09 (Crawled : 11:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -1.21%
H: 0.13%
C: -10.18%
treatment drug extension application review friedreich’s ataxia
Retrospective evaluation of deep transcranial magnetic stimulation as add-on treatment for Parkinson’s disease
Published: 2022-08-08 (Crawled : 19:00) - brainsway.com
BWAY | $5.03 1.93% 1.89% 26K
|
Health Technology
|
| O: -5.22%
H: 4.66%
C: 4.66%
treatment disease
Athersys Announces Favorable Preclinical Results for MultiStem® Treatment in Defense Department Radiation Countermeasure Study and Upcoming Webinar to Review Preclinical Research With MultiStem Across Multiple Indications
Published: 2022-08-08 (Crawled : 14:00) - biospace.com/
ATHX | $0.1018 -40.86% 95M
|
Health Technology
|
| O: 3.74%
H: 12.14%
C: 7.14%
multistem treatment research preclinical defense review study
TRACON Pharmaceuticals Announces Submission of IND Application for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab
Published: 2022-08-08 (Crawled : 13:00) - biospace.com/
TCON | $1.895 2.43% 2.37% 65K
|
Health Technology
|
| O: -2.17%
H: 5.56%
C: 5.56%
yh001 treatment antibody application submission
Global Genital Herpes Treatment Markets, 2022-2027 - Promising Investigational Therapies for Treating Genital Herpes
Published: 2022-08-08 (Crawled : 11:00) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.14%
H: 0.0%
C: 0.0%
treatment global
Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
Published: 2022-08-06 (Crawled : 04:20) - globenewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
| Email alert
Add to watchlist
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
myfembree treatment fda sciences management approval
Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease
Published: 2022-08-05 (Crawled : 13:20) - biospace.com/
TARS | $32.77 -2.79% -2.87% 320K
|
Health Technology
|
| O: -0.87%
H: 2.26%
C: 0.59%
tp-03 treatment disease trial phase 2b
KAZIA THERAPEUTICS REPORTS PROMISING INTERIM DATA FROM COMBINATION STUDY OF PAXALISIB WITH RADIOTHERAPY IN TREATMENT OF BRAIN METASTASES
Published: 2022-08-05 (Crawled : 13:00) - prnewswire.com
KZIA | $0.3951 0.03% 0.03% 100K
|
Health Technology
|
| O: 37.46%
H: 4.92%
C: -23.77%
treatment therapeutics paxalisib study train brain metastases
Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
Published: 2022-08-05 (Crawled : 09:00) - biospace.com/
ACAD | News | $16.57 -1.02% -1.03% 1.3M
|
Health Technology
|
| O: -2.62%
H: 11.57%
C: 8.09%
treatment fda drug disease application alzheimer’s response
Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma
Published: 2022-08-04 (Crawled : 21:00) - globenewswire.com
MRKR | $4.425 5.42% 10K
|
Consumer Services
|
| O: 81.82%
H: 10.0%
C: -10.0%
mt-601 treatment fda clearance therapeutics therapy
BiomX Announces Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel Disease
Published: 2022-08-04 (Crawled : 16:00) - biospace.com/
PHGE | $0.3274 -5.51% 3.82% 130K
|
Health Technology
|
| O: 5.95%
H: 16.37%
C: 0.22%
treatment research disease preclinical publication
NFL Retired Players Association Endorses Halberd Brain Injury Treatment Technology
Published: 2022-08-04 (Crawled : 15:00) - biospace.com/
HALB | $0.0082 7.14% 540K
|
n/a
|
| O: 6.87%
H: 7.14%
C: -7.86%
treatment technology train
Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema
Published: 2022-08-04 (Crawled : 13:00) - biospace.com/
ATXS | $9.02 -6.43% -6.87% 660K
|
Manufacturing
|
| O: 3.23%
H: 2.46%
C: 1.57%
star-0215 treatment antibody trial therapeutics hereditary angioedema
LYNPARZA® (olaparib) Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
Published: 2022-08-04 (Crawled : 11:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: -2.17%
H: 0.42%
C: 0.42%
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: 0.22%
H: 0.09%
C: -1.13%
lynparza treatment approved cancer her2- her2
Syros Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS
Published: 2022-08-03 (Crawled : 00:00) - biospace.com/
SYRS | $5.055 -1.65% -1.68% 90K
|
Health Technology
|
| O: 2.17%
H: 9.03%
C: 5.34%
treatment designation drug positive
REGENXBIO Announces Intention to File a Biologics License Application Using the Accelerated Approval Pathway for RGX-121, an AAV Therapeutic for the Treatment of MPS II
Published: 2022-08-03 (Crawled : 19:00) - biospace.com/
RGNX | $16.05 0.94% 0.93% 350K
|
Health Technology
|
| O: 3.4%
H: 6.37%
C: 3.34%
rgx-121 treatment application license approval mps-ih
Amylyx Pharmaceuticals Announces FDA Advisory Committee Will Reconvene to Review New Drug Application for AMX0035 for the Treatment of ALS on September 7, 2022
Published: 2022-08-03 (Crawled : 14:20) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M
|
|
| O: 1.35%
H: 4.39%
C: -5.53%
amx0035 treatment fda drug als application review
Sorrento Completes Successfully the SAD Study and Initiates the MAD Phase 1 Study with STI-1558, An Oral M(pro) Inhibitor as a Standalone Treatment and Prevention of COVID-19 without the Ritonavir as Booster
Published: 2022-08-03 (Crawled : 13:20) - globenewswire.com
SRNE | $0.015 -8.85% 56K
|
Health Technology
|
| O: 0.77%
H: 8.32%
C: 2.3%
sti-1558 covid-19 treatment study
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.